Sofinnova Investments, Inc. - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 89 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Sofinnova Investments, Inc. ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$11,958,815
-19.7%
2,194,2780.0%0.75%
-22.7%
Q2 2023$14,899,148
+35.5%
2,194,2780.0%0.98%
+38.8%
Q1 2023$10,993,333
+2.7%
2,194,2780.0%0.70%
+10.7%
Q4 2022$10,708,077
-66.2%
2,194,2780.0%0.64%
-65.5%
Q3 2022$31,641,000
-4.7%
2,194,2780.0%1.84%
-33.4%
Q2 2022$33,199,000
+27.4%
2,194,2780.0%2.76%
+39.8%
Q1 2022$26,068,000
-26.7%
2,194,2780.0%1.98%
-4.8%
Q4 2021$35,569,000
-43.2%
2,194,2780.0%2.08%
-44.0%
Q3 2021$62,625,000
-15.6%
2,194,2780.0%3.71%
-13.2%
Q2 2021$74,167,000
+11.8%
2,194,2780.0%4.28%
+7.2%
Q1 2021$66,355,000
-38.9%
2,194,2780.0%3.99%
-38.3%
Q4 2020$108,639,000
+29.0%
2,194,2780.0%6.47%
+3.5%
Q3 2020$84,238,000
-11.1%
2,194,2780.0%6.25%
+4.5%
Q2 2020$94,793,000
+65.5%
2,194,2780.0%5.98%
+12.8%
Q1 2020$57,271,000
-16.5%
2,194,2780.0%5.30%
+7.2%
Q4 2019$68,571,000
+25.0%
2,194,278
+4.3%
4.94%
-0.3%
Q3 2019$54,837,000
+13.9%
2,104,2780.0%4.96%
+12.1%
Q2 2019$48,125,000
-12.7%
2,104,2780.0%4.42%
-16.8%
Q1 2019$55,153,000
+28.9%
2,104,2780.0%5.32%
-0.3%
Q4 2018$42,801,000
-23.4%
2,104,2780.0%5.33%
+7.0%
Q3 2018$55,890,0002,104,2784.98%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Memorial Sloan Kettering Cancer Center 191,176$932,9393.08%
Sofinnova Investments, Inc. 2,194,278$10,708,0770.64%
Artal Group S.A. 400,000$1,9520.11%
Polar Capital Holdings Plc 1,991,929$9,720,6140.08%
ASHFORD CAPITAL MANAGEMENT INC 98,870$482,4860.08%
Soleus Capital Management, L.P. 87,182$425,4480.06%
GSA CAPITAL PARTNERS LLP 99,160$4840.06%
Cormorant Asset Management, LP 150,000$7320.05%
CORNERCAP INVESTMENT COUNSEL INC 48,233$235,3770.04%
XTX Topco Ltd 38,574$188,2410.04%
View complete list of Y-MABS THERAPEUTICS INC shareholders